Summit Therapeutics (LON:SUMM) released its earnings results on Tuesday. The company reported GBX (8) (($0.11)) earnings per share for the quarter, beating analysts’ consensus estimates of GBX (10.60) (($0.14)) by GBX 2.60 ($0.03), Bloomberg Earnings reports. Summit Therapeutics had a negative return on equity of 72.51% and a negative net margin of 102.61%.
Shares of LON:SUMM traded down GBX 2.50 ($0.03) during trading on Thursday, reaching GBX 195 ($2.60). 5,768 shares of the company traded hands, compared to its average volume of 34,608. Summit Therapeutics has a 52 week low of GBX 140 ($1.86) and a 52 week high of GBX 269.70 ($3.59).
In related news, insider Prof Stephen Davies bought 17,500 shares of the business’s stock in a transaction dated Monday, April 23rd. The stock was purchased at an average cost of GBX 126 ($1.68) per share, for a total transaction of £22,050 ($29,356.94).
About Summit Therapeutics
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.